A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
Information source: Diabetic Retinopathy Clinical Research Network
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetic Macular Edema
Intervention: Focal laser photocoagulation (Procedure); 40mg triamcinolone (Drug); 20mg triamcinolone (Drug); 40mg triamcinolone + laser (Drug); 20mg triamcinolone + laser (Drug)
Phase: Phase 2
Sponsored by: Diabetic Retinopathy Clinical Research Network
Official(s) and/or principal investigator(s):
Emily Chew, M.D., Study Chair, Affiliation: National Eye Institute (NEI)
The study involves the enrollment of patients over 18 years of age with diabetic macular
edema involving the center of the macula who have not already been given maximal laser
Patients with one study eye will be randomly assigned (stratified by prior laser) with equal
probability to one of five treatment groups:
1. Focal laser photocoagulation (modified ETDRS technique)
2. Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
3. Anterior peribulbar injection of 20 mg triamcinolone
4. Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
5. Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
For patients with two study eyes (both eyes eligible at the time of randomization), the
right eye (stratified by prior laser) will be randomly assigned with equal probabilities to
one of the five treatment groups listed above. If the right eye was assigned to laser only,
then the left eye will be assigned to one of the four triamcinolone groups above with equal
probability (stratified by prior laser). If the right eye was assigned to receive
triamcinolone, then the left eye will receive laser only.
Triamcinolone acetonide will be the corticosteroid utilized in this study. The triamcinolone
acetonide preparation to be used is Kenalog. Kenalog is manufactured by Bristol Myers Squibb
and is approved by the Food and Drug Administration for intramuscular use for a variety of
indications. Peribulbar injections of Kenalog have been used for a wide variety of ocular
conditions, particularly uveitis and post-cataract extraction cystoid macular edema, for
Two different triamcinolone regimens will be assessed in the study: 40 mg injected
posteriorly and 20 mg injected anteriorly. There is no indication of which treatment regimen
will be better. Although the injection behind the eye is more common than the injection near
the front of the eye, the injection near the front of the eye has less risk of injuring the
eye. However, it is possible that the injection near the front of the eye may increase eye
pressure more frequently. Little is known about which of the two injections decreases
macular edema and improves vision more often.
Patients enrolled into the study will be followed for three years and will have study visits
1 month, 2 months, 4 months, 8 months and annually after receiving their assigned study
treatment. For the first 8 months of the study, patients should only be retreated with their
randomized treatment. However, if the patient's visual acuity has decreased by 15 letters or
more, then any treatment may be given at the investigator's discretion. After completion of
the 8-month visit, treatment is at investigator discretion.
The primary objective of this study is to obtain estimates of efficacy and safety outcomes
for each of the treatment groups. These estimates will provide a basis for the sample size
estimation and hypothesis generation in a phase III trial.
Official title: A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Change in Central Subfield Thickening From Baseline Through 34 Weeks
Change in Visual Acuity Letter Score From Baseline Through 34 Weeks
Mean Visual Acuity Letter Score at Each Follow-up Visit
Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks
Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks
Central Subfield Thickness <250 Microns From Baseline Through 34 Weeks
Diabetic retinopathy is a major cause of visual impairment in the United States. Diabetic
macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central
vision. Data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) estimate
that after 15 years of known diabetes, the prevalence of diabetic macular edema is
approximately 20% in patients with type 1 diabetes mellitus (DM), 25% in patients with type
2 DM who are taking insulin, and 14% in patients with type 2 DM who do not take insulin.
Diabetic macular edema results from abnormal leakage of macromolecules, such as
lipoproteins, from retinal capillaries into the extravascular space followed by an oncotic
influx of water into the extravascular space. Abnormalities in the retinal pigment
epithelium may also cause or contribute to diabetic macular edema. These abnormalities may
allow increased fluid from the choriocapillaries to enter the retina or they may decrease
the normal efflux of fluid from the retina to the choriocapillaris. The mechanism of
breakdown of the blood retina barrier at the level of the retinal capillaries and the
retinal pigment epithelium may be due to changes to tight junction proteins such as
The increase in retinal capillary permeability and subsequent retinal edema may be the
result of a breakdown of the blood retina barrier mediated in part by vascular endothelial
growth factor (VEGF), a 45 kD glycoprotein. Aiello et al, demonstrated in an in vivo model
that VEGF can increase vascular permeability. Fifteen eyes of 15 albino Sprague-Dawley rats
received an intravitreal injection of VEGF. The effect of intravitreal administration of
VEGF on retinal vascular permeability was assessed by vitreous fluorophotometry. In all 15
eyes receiving an intravitreal injection of VEGF, a statistically significant increase in
vitreous fluorescein leakage was recorded. In contrast, control eyes, which were fellow eyes
injected with vehicle alone, did not demonstrate a statistically significant increase in
vitreous fluorescein leakage. Vitreous fluorescein leakage in eyes injected with VEGF
attained a maximum of 227% of control levels.
Antonetti et al, demonstrated that VEGF may regulate vessel permeability by increasing
phosphorylation of tight junction proteins such as occludin and zonula occluden 1.
Sprague-Dawley rats were given intravitreal injections of VEGF and changes in tight junction
proteins were observed through Western blot analysis. Treatment with alkaline phosphatase
revealed that these changes were caused by a change in phosphorylation of tight junction
proteins. This model provides, at the molecular level, a potential mechanism for
VEGF-mediated vascular permeability in the eye. Similarly, in human non-ocular disease
states such as ascites, VEGF has been characterized as a potent vascular permeability factor
The normal human retina contains little or no VEGF; however, hypoxia causes upregulation of
VEGF production. Vinores et al, using immunohistochemical staining for VEGF, demonstrated
that increased VEGF staining was found in retinal neurons and retinal pigment epithelium in
human eyes with diabetic retinopathy.
As the above discussion suggests, attenuation of the effects of VEGF provides a rationale
for treatment of macular edema associated with diabetic retinopathy. Corticosteroids, a
class of substances with anti-inflammatory properties, have been demonstrated to inhibit the
expression of the VEGF gene. In a study by Nauck et al, the platelet-derived growth-factor
(PDGF) induced expression of the VEGF gene in cultures of human aortic vascular smooth
muscle cells was abolished by corticosteroids in a dose-dependent manner. A separate study
by Nauck et al demonstrated that corticosteroids abolished the induction of VEGF by the
pro-inflammatory mediators PDGF and platelet-activating factor (PAF) in a time and
dose-dependent manner. This study was performed using primary cultures of human pulmonary
fibroblasts and pulmonary vascular smooth muscle cells.
As discussed above, corticosteroids have been experimentally shown to down regulate VEGF
production and possibly reduce breakdown of the blood-retinal barrier. Similarly, steroids
have anti-angiogenic properties possibly due to attenuation of the effects of VEGF. Both of
these steroid effects have been utilized. For example, triamcinolone acetonide is often used
clinically as a periocular injection for the treatment of cystoid macular edema (CME)
secondary to uveitis or as a result of intraocular surgery. In animal studies, intravitreal
triamcinolone acetonide has been used in the prevention of proliferative vitreoretinopathy
and retinal neovascularization. Intravitreal triamcinolone acetonide has been used
clinically in the treatment of proliferative vitreoretinopathy and choroidal
Minimum age: 18 Years.
Maximum age: N/A.
Subject Level Criteria Inclusion
To be eligible, the following inclusion criteria (1-4) must be met:
1. Age ≥18 years
2. Diagnosis of diabetes mellitus (type 1 or type 2)
3. At least one eye meets the study eye criteria
4. Able and willing to provide informed consent.
Study Level Exclusion Criteria
A patient is not eligible if any of the following exclusion criteria (5-13) are
5. History of chronic renal failure requiring dialysis or kidney transplant.
6. A condition that, in the opinion of the investigator, would preclude participation in
the study (e. g., unstable medical status including blood pressure and glycemic
control). Patients in poor glycemic control who, within the last 4 months, initiated
intensive insulin treatment (a pump or multiple daily injections) or plan to do so in
the next 4 months should not be enrolled.
7. Participation in an investigational trial within 30 days of study entry that involved
treatment with any drug that has not received regulatory approval at the time of
8. Known allergy to any corticosteroid or any component of the delivery vehicle.
9. History of systemic (e. g., oral, IV, IM, epidural, bursal) corticosteroids within 4
months prior to randomization or topical, rectal, or inhaled corticosteroids in
current use more than 2 times per week.
10. History of steroid-induced intraocular pressure elevation that required IOP-lowering
treatment in either eye.
11. Warfarin (coumadin) currently being used.
12. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood
pressure is brought below 180/110 by anti-hypertensive treatment, patient can become
13. Patient is expecting to move out of the area of the clinical center to an area not
covered by another clinical center during the next 8 months.
The patient must have at least one eye meeting all of the inclusion criteria (a-e)
and none of the exclusion criteria (f-t) listed below:
Study Eye Inclusion Criteria
1. Best corrected electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS)
visual acuity score of ≥69 letters (i. e., 20/40 or better).
2. Definite retinal thickening due to diabetic macular edema based on clinical
3. Retinal thickness in the Optical Coherence Tomography (OCT) central subfield
measuring 250 microns or more.
4. Maximal laser has not already been given and investigator believes that either
peribulbar steroids or laser may benefit the eye (note: subjects may be enrolled
without having received prior macular laser).
5. Media clarity, pupillary dilation, and patient cooperation sufficient for
adequate fundus photographs and OCT.
Study Eye Exclusion Criteria
6. Macular edema is considered to be due to a cause other than diabetic macular
7. An ocular condition is present such that, in the opinion of the investigator,
visual acuity would not improve from resolution of macular edema (e. g., foveal
atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal
8. An ocular condition is present (other than diabetes) that, in the opinion of the
investigator, might affect macular edema or alter visual acuity during the
course of the study (e. g., vein occlusion, uveitis or other ocular inflammatory
disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.).
9. History of prior treatment with intravitreal, peribulbar, or retrobulbar
corticosteroids for DME.
10. History of focal/grid macular photocoagulation within 15 weeks (3. 5 months)
prior to randomization. Note: Patients are not required to have had prior
macular photocoagulation to be enrolled.
11. History of panretinal scatter photocoagulation (PRP) within 4 months prior to
randomization or anticipated need for PRP in the 4 months following
m. History of prior vitrectomy.
n. History of major ocular surgery (including cataract extraction, scleral buckle,
any intraocular surgery, etc.) within prior 6 months or anticipated within the next 6
months following randomization.
o. History of YAG capsulotomy performed within 2 months prior to randomization.
p. Intraocular pressure ≥25 mmHg.
q. History of open-angle glaucoma (either primary open-angle glaucoma or other cause
of open-angle glaucoma; note: angle-closure glaucoma is not an exclusion). A history
of ocular hypertension is not an exclusion as long as (1) intraocular pressure is <25
mm Hg, (2) the patient is using no more than one topical glaucoma medication, (3) the
most recent visual field, performed within the last 12 months, is normal (if
abnormalities are present on the visual field they must be attributable to the
patient's diabetic retinopathy), and (4) the optic disc does not appear glaucomatous.
Note: if the intraocular pressure is 22 to <25 mm Hg, then the above criteria for
ocular hypertension eligibility must be met.
r. History of prior herpetic ocular infection.
s. Exam evidence of ocular toxoplasmosis.
t. Exam evidence of pseudoexfoliation.
A patient may have two "study eyes" only if both are eligible at the time of
Locations and Contacts
Starting date: December 2004
Last updated: May 12, 2011